Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma

Leukemia

Volumn 24, Issue 7, 2010, Pages 1343-1349

  Porrata, L F ^a   Rsitow, K ^a   Inwards, D J ^a   Ansell, S M ^a   Micallef, I N ^a   Johnston, P B ^a   Habermann, T M ^a   Witzig, T E ^a   Colgan, J P ^a   Nowakowski, G S ^a   Thompson, C A ^a   Markovic, S N ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

absolute lymphocyte count; diffuse large B cell lymphoma; relapse

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE; CHEMICALLY INDUCED; IMMUNOLOGY; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPENIA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; VINCRISTINE; YOUNG ADULT;

EID: 77954656902     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.108     Document Type: Article

References (19)

1. National Comprehensive Cancer Network (NCCN). Diffuse large B-cell lymphoma. Practice Guidelines in Oncology-v1.2010.
2. Tilly H, Dreying M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(suppl 4): iv110-iv112: doi:10.1093/annonc/mdp145.
3. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
4. Schoulten HC. Response evaluation and long term follow-up. Ann Oncol 2007;18(Suppl 1): i33-i36.
5. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G et al. A predictive model for aggressive NHL: The International non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
6. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RJ et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
7. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
8. Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieves a complete remission. J Clin Oncol 1991;9:1196-1203.
9. Cox MC, Nofroni I, LaVerde G, Ferrari A, Amodeo R, Tatarelli C et al. Absolute lymphocyte count is a prognostic factor for diffuse large B-cell lymphoma. Br J Haematol 2008;141:265-268.
10. Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma 2008;49:745-751.
11. Oki Y, Yamamoto K, Kato H, Kuwatsula Y, Taji H, Kagami Y et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients survival benefit from rituximab. Eur J Haematol 2008;81:448-453.
12. Cox CJ, Habermann TM, Payne BA, Klee GG, Pierre RV. Evaluation of the Coulter counter model S-Plus IV. Am J Clin Pathol 1985;84:297-306.
13. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med 1999;18:695-706.
14. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008;26:4027-4034.
15. Ghosh D. Proportional hazards regression for cancer studies. Biometrics 2008;64:141-148.
16. Habermann TM. Posttransplant lymphoproliferative disorders. Cancer Treat Res 2008;142:273-292.
17. Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol 2007;137:409-415.
18. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-242.
19. Habermann TM, Weler EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.